Myasthenia Gravis Drugs - Global Strategic Business Report

Global Myasthenia Gravis Drugs Market to Reach $3.1 Billion by 2030

The global market for Myasthenia Gravis Drugs estimated at US$1.8 Billion in the year 2022, is projected to reach a revised size of US$3.1 Billion by 2030, growing at a CAGR of 6.6% over the analysis period 2022-2030. Drug Treatment, one of the segments analyzed in the report, is projected to record 7.2% CAGR and reach US$1.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Rapid Immunotherapies segment is readjusted to a revised 5.9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $553.5 Million, While China is Forecast to Grow at 6.2% CAGR

The Myasthenia Gravis Drugs market in the U.S. is estimated at US$553.5 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$530.1 Million by the year 2030 trailing a CAGR of 6.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.3% and 5.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.

Select Competitors (Total 18 Featured) -

• Alexion Pharmaceuticals, Inc.
• Bausch Health Companies, Inc.
• Catalyst Pharmaceuticals, Inc.
• CSL Limited
• Curavac Inc.
• Cytokinetics, Inc.
• F. Hoffmann-La Roche AG
• Flamel Technologies S.A.
• Galenica Ltd.
• GlaxoSmithKline PLC
• Grifols SA
• Lupin Pharmaceuticals, Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis International AG
• Pfizer, Inc.
• Shire PLC

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year